Hedera Dx raises €14 million in seed funding to accelerate global adoption of liquid biopsies
23-Sep-2022 -
Liquid biopsy cancer testing is one of the most transformational innovations in healthcare for the next decade, directly unlocking better outcomes for patients.
Swiss techbio companyHedera Dx, founded in 2021 by veteran healthcare entrepreneurs and executives, will be launching this fall a ...
blood tests
cancer
cancer diagnostics
+3